PDS Biotechnology Corporation (PDSB)Healthcare | Biotechnology | Princeton, United States | NasdaqCM
1.13 USD
-0.17
(-13.077%) ⇩
(Oct. 16, 2026, 4 p.m.
EDT)
After hours: 1.11 -0.02 (-0.024%) ⇩ (Oct. 16, 2026, 7:52 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 7:07 a.m. EDT
The fundamental reality here is stark: this biotech firm is burning cash, has negative equity, and has suffered a catastrophic 99.5% decline over the last nine years. Despite the 'strong buy' analyst rating, which appears to be based on a single optimistic view of a potential clinical breakthrough, the balance sheet is fragile with a current ratio below 0.6. The recent price action shows a volatile bounce from the lows, but the underlying business quality metrics—negative ROE and free cash flow—are unambiguously poor. The options market reflects this uncertainty with heavy bets on both a miraculous surge to $2.50 and a crash to $0.50, ignoring the statistical forecast entirely. This is not a buy-and-hold opportunity; it is a speculative gamble on a specific future event that could leave shareholders with nothing. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.507122 |
| AutoTheta | 0.528909 |
| MSTL | 0.621516 |
| AutoETS | 0.627193 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 22% |
| H-stat | 18.48 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.222 |
| Excess Kurtosis | -0.93 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 81,895,856 |
| Forward P/E | -3.28 |
| Beta | 1.17 |
| Website | https://www.pdsbiotech.com |
As of Oct. 10, 2026, 7:07 a.m. EDT: Speculators are positioning for a binary event or a sharp recovery rather than steady appreciation. There is heavy open interest in out-of-the-money calls at the $2.50 strike for late 2027, suggesting a belief in a massive rally to double the current price. Conversely, deep out-of-the-money put walls exist at the $0.50 strike, indicating a hedge against a collapse back to pennies. The lack of significant open interest near the current price suggests the market views the current level as a pivot point where the next move will be extreme in either direction.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.15423906 |
| Address1 | 303A College Road East |
| All Time High | 517.4 |
| All Time Low | 0.195 |
| Ask | 1.12 |
| Ask Size | 1 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 18,076,780 |
| Average Daily Volume3 Month | 24,383,496 |
| Average Volume | 24,383,496 |
| Average Volume10Days | 18,076,780 |
| Beta | 1.168 |
| Bid | 1.45 |
| Bid Size | 6 |
| Book Value | -0.064 |
| City | Princeton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.13 |
| Current Ratio | 0.569 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 1.26 |
| Day Low | 1.0904 |
| Display Name | PDS Biotechnology |
| Dividend Date | 1,552,867,200 |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,778,673,600 |
| Earnings Call Timestamp Start | 1,778,673,600 |
| Earnings Timestamp | 1,786,624,200 |
| Earnings Timestamp End | 1,794,486,600 |
| Earnings Timestamp Start | 1,794,486,600 |
| Ebitda | -27,772,152 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.233 |
| Enterprise Value | 62,015,028 |
| Eps Current Year | -0.49 |
| Eps Forward | -0.345 |
| Eps Trailing Twelve Months | -0.64 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.62144 |
| Fifty Day Average Change | 0.50856 |
| Fifty Day Average Change Percent | 0.81835735 |
| Fifty Two Week Change Percent | 15.423906 |
| Fifty Two Week High | 1.79 |
| Fifty Two Week High Change | -0.65999997 |
| Fifty Two Week High Change Percent | -0.36871508 |
| Fifty Two Week Low | 0.195 |
| Fifty Two Week Low Change | 0.935 |
| Fifty Two Week Low Change Percent | 4.794872 |
| Fifty Two Week Range | 0.195 - 1.79 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,443,619,800,000 |
| Float Shares | 44,836,400 |
| Forward Eps | -0.345 |
| Forward P E | -3.2753623 |
| Free Cashflow | -13,760,966 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 21 |
| Fullday Change | -0.194 |
| Fullday Change Percent | -14.923079 |
| Fullday Price | 1.13 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.19108999 |
| Held Percent Institutions | 0.10751 |
| Implied Shares Outstanding | 72,474,208 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,552,867,200 |
| Last Split Factor | 1:20 |
| Long Business Summary | PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, Georgia Research Foundation, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey. |
| Long Name | PDS Biotechnology Corporation |
| Market | us_market |
| Market Cap | 81,895,856 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_53742727 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -33,671,960 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 59,707,876 |
| Number Of Analyst Opinions | 1 |
| Open | 1.25 |
| Operating Cashflow | -16,782,788 |
| Operating Margins | 0.0 |
| Phone | 800 208 3343 |
| Post Market Change | -0.024000049 |
| Post Market Change Percent | -2.123898 |
| Post Market Price | 1.106 |
| Post Market Time | 1,792,194,778 |
| Previous Close | 1.3 |
| Price Eps Current Year | -2.3061223 |
| Price Hint | 4 |
| Price To Book | -17.65625 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.452 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.17 |
| Regular Market Change Percent | -13.0769 |
| Regular Market Day High | 1.26 |
| Regular Market Day Low | 1.0904 |
| Regular Market Day Range | 1.0904 - 1.26 |
| Regular Market Open | 1.25 |
| Regular Market Previous Close | 1.3 |
| Regular Market Price | 1.13 |
| Regular Market Time | 1,792,180,800 |
| Regular Market Volume | 6,837,412 |
| Return On Assets | -0.70594 |
| Return On Equity | -5.4397197 |
| Sand P52 Week Change | 0.13723719 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 72,474,208 |
| Shares Percent Shares Out | 0.0382 |
| Shares Short | 2,770,411 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 2,349,694 |
| Short Name | PDS Biotechnology Corporation |
| Short Percent Of Float | 0.039300002 |
| Short Ratio | 0.05 |
| Source Interval | 15 |
| State | NJ |
| Symbol | PDSB |
| Target High Price | 5.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 5.0 |
| Target Median Price | 5.0 |
| Total Cash | 5,596,254 |
| Total Cash Per Share | 0.1 |
| Total Debt | 4,363,672 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.64 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.814725 |
| Two Hundred Day Average Change | 0.315275 |
| Two Hundred Day Average Change Percent | 0.3869711 |
| Type Disp | Equity |
| Volume | 6,837,412 |
| Website | https://www.pdsbiotech.com |
| Zip | 8,540 |